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Abstract 
Elevated C-reactive protein (CRP), a non-specific biomarker of systemic bodily inflammation, has 
been associated with more pronounced cognitive impairments in adults with psychiatric 
disorders, particularly in the domains of memory and executive function. Whether this 
association is present in early life (i.e., the time at which the cognitive impairments that 
characterise these disorders become evident), and is specific to those with emerging psychiatric 
disorders, has yet to be investigated. To this end, we examined the association between salivary 
CRP and cognitive function in children aged 11- 14 years and explored the moderating effect of 
psychopathology. The study utilised data from an established longitudinal investigation of 
children recruited from the community (N=107) that had purposively over-sampled individuals 
experiencing psychopathology (determined using questionnaires). CRP was measured in saliva 
samples and participants completed assessments of cognition (memory and executive function) 
and psychopathology (internalising and externalising symptoms and psychotic-like experiences). 
Linear regression models indicated that higher salivary CRP was associated with poorer letter 
fluency (β=-0.24, p=0.006) and scores on the inhibition (β=-0.28, p=0.004) and 
inhibition/switching (β=-0.36, p<0.001) subtests of the colour-word interference test, but not 
with performance on any of the memory tasks (working, visual, and verbal memory tasks). 
Results were largely unchanged after adjustment for psychopathology and no significant 
interactions between CRP and psychopathology were observed on any cognitive measure. Our 
findings provide preliminary evidence that elevated salivary CRP is associated with poorer 
cognitive function in early life, but that this association is not moderated by concurrent 
psychopathology. These findings have implications for early intervention strategies that attempt 
to ameliorate cognitive deficits associated with emerging psychiatric disorders. Further research 
is needed to determine whether salivary CRP levels can be used as a valid marker of peripheral 
inflammation among healthy adolescents.   
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1. Introduction 
Over the past decade, there have been increased efforts to elucidate the role of 
inflammatory processes in both the pathogenesis and symptomology of psychiatric disorders 
(Haroon et al., 2012). These efforts have demonstrated that a number of psychiatric disorders, 
including schizophrenia, bipolar disorder, and depression, are characterised by elevated 
concentrations of C-reactive protein (CRP), a non-specific biomarker of systemic bodily 
inflammation (Fernandes et al., 2016a, Fernandes et al., 2016b, Howren et al., 2009). Moreover, 
within these populations, elevated CRP is associated with poorer cognitive function. Specifically, 
higher CRP has been found to correlate with greater cognitive impairments, particularly in 
memory and executive function domains, among individuals with schizophrenia (Bulzacka et al., 
2016, Dickerson et al., 2007, Frydecka et al., 2015, Johnsen et al., 2016, Micoulaud-Franchi et al., 
2015); with poorer memory and general cognitive function in those with bipolar disorder 
(Dickerson et al., 2013); and with attention and executive function deficits among individuals 
with depression (Chang et al., 2012, Krogh et al., 2014). Such findings lend support to the notion 
that chronic inflammation may contribute to the cognitive impairments that typically 
characterise these disorders; however, two major questions remain unanswered: Firstly, to 
what extent is the association between CRP and cognition specific to those with psychiatric 
disorders? Secondly, is this association present during early life? The latter is particularly 
pertinent given that the cognitive impairments observed among individuals with these disorders 
emerge during childhood, many years before disorder onset (Dickson et al., 2012, Koenen et al., 
2009, Laurens et al., 2015). 
Studies examining the relationship between CRP and cognition among those without 
psychiatric disorders have typically focused on distinct sub-populations characterised by 
cognitive impairments. Much research has focused on healthy older adults (≥50 years); both 
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cross-sectional and longitudinal studies indicate that elevated CRP is associated with poorer 
cognitive function in this population (Jenny et al., 2012, Marioni et al., 2009, Noble et al., 2010, 
Schram et al., 2007, Teunissen et al., 2003), though the association is rendered non-significant 
after adjustment for sociodemographic factors in some studies (Alley et al., 2008, Dik et al., 
2005, Kao et al., 2011). Whilst a small number of these studies assessed depression symptoms, 
none examined the effect of these symptoms on the relationship between CRP and cognition; 
thus, the extent to which this relationship might be explained by psychiatric morbidity is 
unknown. Other studies have focused on populations with specific medical conditions. In cross-
sectional investigations, CRP has been associated with poorer cognitive ability (again, 
particularly in the domains of memory and executive function) in preterm infants (O'Shea et al., 
2013, Rose et al., 2016), infants with congenital heart problems (Li et al., 2014), children with 
obstructive sleep apnoea (Huang et al., 2016), and in adults experiencing mild traumatic brain 
injury (Su et al., 2014) or chronic obstructive pulmonary disease (Crisan et al., 2014). 
Inconsistent findings characterise studies examining populations that are neither exclusively 
older in age nor characterised by physical health conditions. A study of adults aged 18-82 years 
reported that CRP was not associated with executive function abilities (Schuur et al., 2010), 
whilst another large study of 28-91 year olds observed negative correlations between CRP and 
slower processing speed (but not executive function or memory performance) among African 
American (but not European American) participants (Windham et al., 2014). Only two studies, 
both longitudinal, have focused on young individuals from the general population; CRP did not 
predict memory or executive function in a two-year follow-up of adolescents (Jonker et al., 2014) 
or global cognition in a 13-year follow-up of young adults (Cohen-Manheim et al., 2015).  
Thus, whilst elevated CRP has been associated with greater cognitive impairment in some 
non-psychiatric samples, the association appears to be restricted to populations in which 
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cognitive impairment is also prevalent (e.g., older adults and those with physical health 
conditions). In contrast, a lack of evidence exists to suggest that CRP predicts later cognitive 
function in adolescents and young adults in the general population, which may reflect follow-up 
periods exceeding two years that were employed in these studies. However, the only previous 
study of adolescents did not investigate whether the relationship was present among those 
experiencing psychopathology (e.g., depression or subclinical psychotic symptoms). This is 
important, as opportunities for intervening to improve cognitive deficits associated with 
psychiatric disorders (either by psychological or biological means) are likely to be maximised in 
early life.  
In light of these issues, the current study sought to investigate associations between 
inflammation, cognitive impairments, and emerging psychopathology in childhood, utilising 
salivary CRP as a marker of inflammation. Salivary CRP offers a less-invasive alternative to blood-
based CRP measurement, particularly in child/adolescent populations in which there is often 
reluctance to provide blood samples. With the exception of a single study of healthy adults that 
failed to find an association between salivary and serum CRP (Dillon et al., 2010), most previous 
studies have demonstrated moderate-to-high correspondence between CRP levels in 
serum/plasma and saliva (Byrne et al., 2013, Iyengar et al., 2014, Ouellet-Morin et al., 2011, Out 
et al., 2012). The linear relationship observed between CRP in blood and saliva in these studies 
implies that the latter is a valid marker of peripheral inflammation. Nonetheless, the origin of 
salivary CRP is currently unclear. It has been proposed that CRP derived from saliva samples may 
reflect systemic CRP (predominately produced by the liver) that has leaked into gingival 
crevicular fluid via gingival tissues, though salivary CRP might also be produced by gingival 
tissues in response to periodontal infections (Salimetrics, 2011). By utilising salivary CRP as a 
marker of inflammation, the current study provides an opportunity to determine whether 
associations observed between blood-derived CRP and cognition extend to salivary CRP.   
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Capitalizing on a well-established longitudinal study of children recruited from the 
community (Laurens and Cullen, 2016), we examined the effect of salivary CRP on measures of 
memory and executive function in a sample of children aged 11-14 years that was enriched for 
children presenting with psychopathology (as determined using screening questionnaires). We 
first examined the predictive effect of salivary CRP on memory and executive function after 
adjusting for various methodological and participant factors that might confound the 
association. We then explored interactions between salivary CRP and psychopathology domains 
(internalising and externalising symptoms and psychotic-like experiences) to determine whether 
any associations between CRP and cognitive performance differed among children with and 
without psychopathology. We predicted that, in this sample of adolescents enriched for 
psychopathology, higher salivary CRP would be associated with poorer memory and executive 
function. We also anticipated that concurrent psychopathology would moderate the association 
between CRP and these cognitive functions.  
2. Materials and Methods 
2.1. Participants and procedure 
The current study uses data from an established longitudinal investigation of children initially 
recruited from the general population of South London at age 9-12 years (Laurens and Cullen, 
2016, Laurens et al., 2007, Laurens et al., 2011). From the community sample of 1,343 children 
and caregivers completing screening, a subset of these participants were selected (N=123) to 
participate in laboratory-based assessments conducted at the Institute of Psychiatry, Psychology 
& Neuroscience, King’s College London, UK. This intensely-studied sample was enriched with 
children presenting with psychopathology [developmental delays (Laurens et al., 2007); social, 
emotional, and/or behavioural problems (Goodman, 2001); and psychotic-like experiences 
(Laurens et al., 2012)] and/or a family history of psychosis [confirmed using the Family Interview 
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for Genetic Studies (Maxwell, 1992)]; the sample also included unaffected children without 
psychopathology or family history of psychosis (44% of those initially recruited to the study). 
Children with a neurological condition (e.g., epilepsy or cerebral palsy), autism, Asperger’s 
disorder, or a diagnosed learning disability were not eligible to participate. Laboratory 
assessments comprising a variety of biological and psychosocial measures were completed 
biennially throughout adolescence in this cohort. The current study examines data obtained at a 
follow-up assessment completed at age 11-14 years, and includes participants who provided at 
least one saliva sample at this assessment phase and completed the cognitive measures 
described below (N=107).  
At this assessment phase, children and their caregivers provided written informed assent and 
consent, respectively, for participation. Ethical permission for the study was granted by the Joint 
South London and Maudsley and the Institute of Psychiatry NHS Research Ethics Committee. 
Caregivers provided information on family psychiatric history and participant ethnicity 
[determined using information obtained using the Family Interview for Genetic Studies (Maxwell, 
1992)] and caregiver occupation [coded according to the UK National Statistics Socio-economic 
Classification (Office for National Statistics., 2010)]. Children completed the Pubertal 
Developmental Scale questionnaire (Carskadon and Acebo, 1993) and provided information on 
tobacco and cannabis use via a self-report measure (McVie and Bradshaw, 2005). Height and 
weight were collected by the researcher at the assessment session to compute Body Mass Index 
(BMI; kilograms/metres
2
). The LMS method (Pan and Cole, 2012) was used to convert raw BMI 
data into age- and sex-adjusted standard deviation scores (z scores) using UK growth reference 
data (Cole et al., 1998). Participant BMI z scores were then classified according to clinical 
centiles as follows: very underweight (≤0.4
th
), low weight (≤2
nd
), healthy weight (>2 to <91
st
), 
overweight (≥ 91
st
), obese (≥98
th
), and extremely obese (≥99.6
th
). Obese and extremely obese 
categories were combined for the purposes of the current study.  
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2.2. Salivary C-reactive protein 
2.2.1. Sample collection procedure 
As described previously (Cullen et al., 2014), participants received written instructions for 
collecting saliva samples at home using the passive drool procedure recommended for CRP 
measurement (http://www.salimetrics.com). Participants were asked to collect six saliva 
samples throughout the day on two consecutive days: at awakening, and at 15, 30, and 60 
minutes after awakening, and at 12:00 h, and 20:00 h. Participants were instructed to wake 
before 10:00 h and collect the first sample immediately upon awakening, to avoid food 
consumption for 30 minutes prior to each sample collection, and to refrain from strenuous 
exercise. Using a sampling diary, participants recorded the time of each sample collection, time 
of awakening, and described their activities during the day. Participants were also asked to 
indicate whether they had experienced any general health problems (i.e., headache, tiredness, 
cold, infection, hay fever, allergies, asthma) or dental problems (i.e., toothache, mouth ulcer, 
bleeding gums) during the past week, including the days of sample collection, via a self-report 
checklist. Samples were stored in the participant’s home freezer until collection, and 
subsequently frozen at -20° C at the laboratory for up to five years prior to assay (mean lapse of 
time = 1186 days).  
2.2.2. Salivary CRP assay 
Salivary CRP levels were measured using a commercially available enzyme-linked 
immunoassay kit from Salimetrics, Suffolk, UK, following the recommended procedure. Frozen 
saliva samples were allowed to thaw at room temperature and centrifuged at 3,000 rpm for 15 
minutes to remove mucins. Samples were diluted in the manufacturer’s buffer (1:10) and 
assayed in duplicate, using the Tecan Freedom Evo 100 automated liquid handler. After 2 hours 
of incubation on a microplate coated with anti-CRP antibodies, in the presence of diluted 
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enzyme conjugate solution linked to horseradish peroxidase, wells were washed four times. A 
solution of tetramethylbenzidine was then added and the plate was incubated in the dark for 30 
minutes with continual mixing. After adding a stop solution of sulphuric acid and further mixing 
on a plate rotator for 3 minutes, optical density was read on a Beckman Coulter DTX 880 plate 
reader, with Multimode Detection Software 2.0.012, at 450nm with correction at 620nm. 
SoftMax Pro 4.8 software was used to calculate the CRP values, following a 4-parameter fit. The 
coefficient of variation (CV, calculated as standard deviation*100/mean) was calculated for each 
sample to determine the degree of variation between duplicates.   
2.2.3. CRP sample availability and effect of methodological factors 
Participants were instructed to collect 12 samples over a two-day period, but participant 
non-compliance (i.e., failure to collect all samples) or insufficient saliva available for assay after 
aliquoting reduced the mean number of saliva samples available for CRP assay to 5.67 per 
participant (N=659; range: 1-12). Rather than deriving an average CRP value across all time-
points (which might be influenced by the fact that participants were missing data for different 
time-points), we used the samples obtained at 12:00 on Day 1 to examine the association 
between salivary CRP and cognition as these were the most prevalent. To establish whether it 
was appropriate to use another sample in place of the 12:00 h Day 1 sample (where this sample 
was unavailable), we performed preliminary analyses on the total dataset (N=605 after 
excluding 52 samples with CV values > 20% and 2 samples with extremely high CRP values) to 
determine whether CRP values were influenced by time and day of sampling. In this larger 
dataset, we also investigated the influence of participant demographic factors on CRP levels in 
order to identify potential confounders in the main analysis.  
These preliminary methodological analyses are detailed in the Supplementary Material. In 
brief, a mixed effects linear regression model indicated a significant effect of sampling time on 
salivary CRP levels (CRP values for all other time-points significantly lower relative to the 
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awakening sample, p≤0.02) and a significant effect of day of sampling (CRP levels lower on the 
second day of collection, p<0.001). Neither time of awakening nor length of time in storage 
were associated with CRP. With regards to participant factors, after adjustment for time and day 
of sampling, those who reported recent dental problems were characterised by higher CRP 
(p=0.01); however, CRP was not significantly associated with age, BMI, sex, ethnicity, 
socioeconomic status, recent health problems, or a family history of psychosis. Thus, where a 
12:00 h Day 1 sample was unavailable, data were replaced with any non-awakening sample 
obtained on Day 1 (n=8), a 12:00 h sample collected on Day 2 (n=11), or any other Day 2 sample 
except the awakening sample (n=7). Blood CRP values were estimated using a regression 
equation (y = 1553.15 x - 1413.19; where y = serum CRP and x = salivary CRP) reported in a 
previous study examining the association between salivary and serum CRP in healthy adults 
(Ouellet-Morin et al., 2011). Estimated blood CRP values were calculated in order to identify 
high estimated CRP values [blood CRP > 10 mg/L (Pearson et al., 2003)] likely to be indicative of 
acute inflammation. All estimated blood CRP values were less than 10 mg/L.  
2.3. Cognitive assessments 
Participants completed a battery of cognitive assessments at the research session (typically 
saliva samples were collected by participants during the same week, mean lapse of time 
between cognitive assessment and saliva collection was ± 1.4 months). Selected subtests from 
the Wide Range Assessment of Memory and Learning 2nd Edition [WRAML2 (Sheslow and 
Adams, 2003)] and the Delis–Kaplan Executive Function System [D-KEFS (Delis et al., 2001)] 
were used to assess memory and executive function. Table 1 provides a description of each 
WRAML2 and D-KEFS subtest administered. Standardised scores were derived for each subtest 
using manual-reported population norms.   
[Insert Table 1 about here] 
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2.4. Psychopathology assessments 
Children completed the Youth Self-Report (YSR) for school-aged children (Achenbach and 
Rescorla, 2001), a widely-used measure of psychopathology that has been evaluated extensively 
in child and adolescent populations and exhibits high reliability and validity. The YSR 
incorporates a 112-item checklist of problems occurring during the past six months, each item is 
scored on a three-point scale (0 ‘not true’, 1 ‘somewhat true or sometimes true’, or 2 ‘very true 
or often true’). Item scores can be summed to derive eight empirically-derived syndrome 
subscales: (i) anxious/depressed, (ii) withdrawn/depressed, (iii) somatic complaints, (iv) social 
problems, (v) thought problems, (vi) attention problems, (vii) rule-breaking behaviour, (viii) 
aggressive behaviour; subscale scores can then be combined to obtain two overall scores 
indexing internalising (subscales i, ii, and iii) and externalising problems (subscales vii and viii). 
The YSR provides age- and sex-adjusted normative data that can be used to categorise 
internalising and externalising scale scores as falling within the ‘normal’, ‘borderline’, or ‘clinical’ 
ranges. For the purposes of the current study, we combined the ‘borderline’ and ‘clinical’ groups 
to create binary variables (normal vs. borderline/clinical) for both the internalising and 
externalising subscales.  
Participants additionally completed a nine-item psychotic-like experiences measure (Laurens 
et al., 2012, Laurens et al., 2007). This measure included a range of hallucination- and delusion-
like experiences, each rated on a three-point scale (0 ‘not true’, 1 ‘somewhat true’, or 2 
‘certainly true’). A binary variable was derived indicating the presence of at least one experience 
rated somewhat or certainly true.  
2.5. Statistical analyses 
Analyses were conducted using Stata version 12 (StataCorp, 2011). Cognitive scores, but not 
salivary CRP scores, were approximately normally distributed in the current sample (N=107). 
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Applying a square root transformation to the salivary CRP variable improved the skewness but 
not the kurtosis (values 0.47 and 4.20, respectively), therefore all regression analyses using the 
transformed CRP variable were performed with robust standard errors. Linear regression 
analyses were conducted to examine the association between CRP (independent variable: IV) 
and each cognitive subtest examined (dependent variable: DV); as noted above, all regression 
analyses were adjusted for sampling day and recent dental problems owing to the association of 
these variables with salivary CRP (see Supplementary Material). Standardised beta values (β) are 
presented for ease of comparison across cognitive subtests. In supplementary analyses, the 
association between each psychopathology variable (IV) and CRP (DV) was examined 
(Supplementary Material). We then repeated all analyses examining the effect of CRP on 
cognition with current psychopathology included as additional covariates; in the final step, 
interactions between each psychopathology variable and CRP were included in each model.  
3. Results  
3.1. Sample characteristics  
Demographic characteristics of the sample are displayed in Table 2. The mean age of 
participants at the time of CRP collection was 13.2 years and approximately half (48.1%) were 
male. Consistent with the ethnic diversity known to characterise the population from which 
participants were sampled, one third were of white British ethnicity. Just over one quarter 
(27.1%) had a first- or second-degree relative with a psychotic disorder (schizophrenia, 
schizoaffective disorder, or bipolar disorder). With regards to current psychopathology, 17.1% 
and 10.5% of participants scored in the borderline/clinical range on the YSR internalising and 
externalising scales, respectively, and 43.0% of the sample reported at least one 
somewhat/certainly true psychotic-like experience.  
[Insert Table 2 about here] 
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3.2. Predictive effect of CRP on cognitive performance 
Table 3 presents the results of linear regression analyses examining the association between 
salivary CRP and cognitive performance after adjustment for methodological and demographic 
factors (sampling day and recent dental problems). Analyses indicated a significant association 
between CRP and several measures of executive functioning; specifically, higher salivary CRP 
was associated with lower scores on the letter fluency subtest of the verbal fluency test (β=-0.24, 
p=0.006), with a statistical trend observed also for lower category fluency subtest scores (β=-
0.17, p=0.08). Additionally, higher CRP levels were associated with significantly poorer 
performance on both the inhibition (β=-0.28, p=0.004) and inhibition/switching (β=-0.36, 
p<0.001) subtests of the colour-word interference test. In contrast, CRP was not significantly 
associated with scores on the D-KEFS towers test or performance on any of the WRAML2 
memory measures.  
[Insert Table 3 about here] 
3.3. Association between current psychopathology and CRP 
Linear regression analyses, adjusted for sample day and recent dental problems, indicated 
that internalising problems, externalising problems, and psychotic-like experiences were not 
significantly associated with salivary CRP (p>0.05, Supplementary Material). 
3.4. Effect of current psychopathology on the association between CRP and cognition 
Analyses were next performed to examine the association between salivary CRP and 
cognitive scores after additionally adjusting for psychopathology variables. As shown in Table 3, 
the pattern of results was largely unchanged; salivary CRP remained significantly associated with 
scores on the D-KEFS letter fluency subtest of the verbal fluency test and the D-KEFS inhibition 
and inhibition-switching subtests of the colour-word interference test (p<0.01 for all). The 
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association between CRP level and D-KEFS category fluency subtest scores, however, reduced in 
significance although the standardised beta value did not change (β=-0.17, p=0.10).  
3.5. Moderating effects of psychopathology 
As a final step, interaction terms between CRP and each of the three psychopathology 
domains (internalising and externalising symptoms and psychotic-like experiences) were 
additionally included in each model; however, as no significant interaction effects were 
observed (see Table 3), these were dropped from the final models.  
3.6. Consideration of additional factors 
All analyses were repeated after including lapse of time between cognitive assessment and 
salivary CRP sampling, with no change to the overall pattern of results (i.e., all previously 
reported statistically significant results remained significant). Only one participant in the sample 
may have recently used psychotropic medication (stimulant medication had been prescribed to 
this participant at the current follow-up assessment, which may have been used in the days 
preceding saliva collection); however, none of the participants had taken medication on either 
of the saliva collection days. CRP data for this participant were not outliers within the current 
sample and the results of the main analyses examining the relationship between salivary CRP 
and cognition were unchanged after excluding this participant.   
4. Discussion  
In this sample of children aged 11-14 years, enriched for those presenting with 
psychopathology, we examined the association between salivary CRP and cognitive 
performance, and, for the first time, the extent to which this relationship was modified by 
concurrent psychopathology. Consistent with previous studies examining CRP from blood 
samples, we showed that higher salivary CRP levels are associated with poorer performance on 
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several executive functioning measures, thereby demonstrating the potential utility of salivary 
CRP in populations where there is reluctance to provide blood samples. However, salivary CRP 
was not associated with scores on memory subtests. The pattern of findings was unchanged 
after adjusting for current psychopathology (internalising and externalising symptoms and 
psychotic-like experiences) and we observed no significant interactions between salivary CRP 
and these psychopathology domains. Thus, the current findings provide no evidence to suggest 
that the association of salivary CRP and cognitive function is restricted to, or more pronounced 
among, adolescents characterised by emerging psychopathology.  
Our findings should be interpreted cautiously owing to our use of salivary CRP alone as a 
measure of systemic inflammation. Studies examining the concordance between salivary CRP 
and blood-derived CRP values have yielded mixed findings; whilst most studies have shown 
moderate-to-high correlations (Byrne et al., 2013, Iyengar et al., 2014, Ouellet-Morin et al., 
2011, Out et al., 2012) others have not (Dillon et al., 2010). It is important to note that only one 
of these studies examined adolescents (Byrne et al., 2013). As that study observed significant 
associations between salivary and serum CRP among adolescents with high serum CRP, but not 
those with low serum CRP, the extent to which salivary CRP is a valid marker of systemic 
inflammation in our sample of relatively healthy adolescents is unclear. In light of these findings, 
we do not advocate that researchers measure CRP in saliva only, but rather, when possible, 
measure both salivary and blood CRP levels in order to further test the extent to which salivary 
CRP represents a valid, non-invasive biomarker of systemic inflammation.  
Our extended analyses indicated that salivary CRP levels were not significantly elevated 
among children classified as obese (see Supplementary Material), a finding that has been 
observed in previous studies of children aged 7-12 years (Goodson et al., 2014, Naidoo et al., 
2012). In both previous studies, participant BMI categories were derived from US growth charts 
(Ogden et al., 2002) which differ from the British 1990 categories utilised in the current study 
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(Lang et al., 2011) , potentially contributing to our divergent finding. Alternatively, the fact that 
only a small proportion of our sample were classified as obese (4.8%) may have limited our 
ability to detect significant elevations in CRP in this group. Our use of salivary CRP also meant 
that we were unable to definitively identify participants with high CRP values, indicative of acute 
systemic infection or illness. Whilst we attempted to estimate blood CRP levels using previously-
published data (Ouellet-Morin et al., 2011), further studies are needed to confirm the validity of 
this approach. Nonetheless, we observed robust associations between salivary CRP and 
cognitive function that mirrored those reported in studies utilising blood-derived CRP.  
The current study is the first to demonstrate that CRP measured in saliva is predictive of 
poorer performance on several measures of executive function. Our findings obtained in this 
sample of children enriched for psychopathology are consistent with previous studies in which 
significant associations between blood-derived CRP levels and executive function have been 
observed among individuals with psychiatric disorders (Dickerson et al., 2013, Krogh et al., 2014, 
Micoulaud-Franchi et al., 2015), older adults (Marioni et al., 2009, Schram et al., 2007), and 
children with obstructive sleep apnoea (Huang et al., 2016). Contrary to our hypotheses, salivary 
CRP levels were unrelated to performance on any of the memory measures examined in the 
current study. This is surprising given the wealth of studies that have previously found CRP to be 
associated with memory performance in both psychiatric samples and older adults (Bulzacka et 
al., 2016, Dickerson et al., 2013, Frydecka et al., 2015, Johnsen et al., 2016, Marioni et al., 2009, 
Noble et al., 2010, Teunissen et al., 2003). It is possible that, among healthy adolescents, 
elevated CRP is specifically related to executive function but not memory performance. As 
discussed in detail below, the specific executive function domains examined in the current study 
might be served by brain regions which are particularly sensitive to the effects of elevated CRP 
during adolescence. Alternatively, it may be that our cognitive measures did not capture the 
specific impairments in memory that might be associated with elevations in CRP.    
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Our finding that psychopathology had neither a confounding nor moderating effect on the 
association of CRP and cognitive performance is in contrast to our hypotheses. Given that CRP 
has been associated consistently with cognition in samples of individuals with psychiatric 
disorders (schizophrenia, bipolar disorder, and depression), but not in samples of healthy 
individuals, we expected that the relationship between CRP and cognition would be more 
prominent among those with concurrent psychopathology. We found no evidence to support 
this. This may be due to the fact that the indices of psychopathology that we examined in the 
current study (i.e., scores in the borderline/clinical range of the YSR and the presence of at least 
one somewhat/certainly true psychotic-like experience) were of insufficient severity to 
moderate the effect of CRP on cognitive function. It is possible that clinically-determined 
psychiatric disorders may show interaction effects with CRP. Alternatively, CRP may be 
predictive of poor cognitive performance irrespective of concurrent psychopathology. Given 
that this appears to be the first study to examine potential interaction effects between CRP and 
psychopathology domains, it will be important to conduct similar analyses in larger samples to 
more definitively address these questions.  
To our knowledge, only one previous study has examined the association of CRP and 
cognitive function in adolescents recruited from the general population (Jonker et al., 2014). In 
contrast to the current findings, this large, longitudinal study of 1084 adolescents observed that 
CRP was not associated with memory or executive function at a two-year follow-up. There are 
several possible explanations for why our findings do not concur with this study. Firstly, our 
analyses were cross-sectional; it is possible that within adolescent samples (where cognitive 
function might be expected to change over time) CRP might be associated with concurrent 
cognitive performance only. Secondly, the study by Jonker and colleagues included only a single 
measure of executive functioning (the self-ordered pointing task, (Ross et al., 2007)), which may 
be less sensitive to the effects of inflammation. Finally, our sample was enriched for children 
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presenting with psychopathology; we might therefore expect some individuals within our 
sample to be characterised by poorer cognitive performance relative to the general population. 
However, with the exception of scores on the WRAML2 visual memory index, mean scores on all 
cognitive subtests were higher than the manual-reported means based on normative data (see 
Table 1). Moreover, as noted above, we found no evidence to suggest that psychopathology 
moderated the relationship between CRP and cognitive performance.    
4.1. Potential mechanisms 
Our findings provide tentative support for the suggestion that peripheral inflammation, as 
estimated via salivary CRP, might contribute to impairments in cognitive function. However, the 
mechanisms underlying this process have not been elucidated fully. Whilst it was previously 
thought that the brain was protected from the effects of systemic inflammation and immune 
responses, this has been revised in light of recent evidence that the brain responds to peripheral 
inflammation and that CRP has neurotoxic properties (for a review see (Warnberg et al., 2009)). 
In the current study, we observed that salivary CRP was specifically associated with performance 
on the letter fluency task and the colour-word interference test (similar to the Stroop test; 
(Stroop, 1935)). Meta-analyses of functional MRI studies indicate that these tests are related to 
particular brain regions, largely those located in the frontal lobe. Specifically, letter fluency 
performance is associated with activation of the left inferior/middle frontal gyrus, bilateral 
anterior cingulate, and the right insula/frontal lobe (Wagner et al., 2014), whilst the anterior 
cingulate and inferior frontal junction (bridging the inferior frontal sulcus and the inferior 
precentral sulcus) as well as other frontal regions have been implicated in the colour-word 
Stroop test (Cieslik et al., 2015, Derrfuss et al., 2005). Longitudinal MRI studies indicate that the 
brain continues to grow and reorganise throughout adolescence and that the frontal brain 
regions are among the last to fully mature (Johnson et al., 2009). Thus, one potential reason for 
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why we observed significant associations between salivary CRP and these specific executive 
functioning measures in this adolescent sample is that the frontal brain regions that subserve 
these cognitive abilities are under-developed and therefore particularly vulnerable to the effects 
of CRP. However, it is important to note that in this cross-sectional study it is not possible to 
determine that CRP has a causal effect on cognitive impairment. Moreover, in the absence of 
blood-derived CRP data, our findings cannot provide direct evidence of a relationship between 
systemic inflammation and cognition among relatively healthy adolescents; thus, the 
mechanisms we propose here should be treated as speculative.  
Given that none of the participants exhibited high CRP values indicative of acute infection 
(see Section 2.2.3), one important question relates to how the association between ‘moderately 
elevated’ salivary CRP and executive function should be interpreted. Our finding that salivary 
CRP was not related to recent health problems is consistent with previous studies of healthy 
adults (Ouellet-Morin et al., 2011, Out et al., 2012) and implies that the association is not driven 
by poor general health. Accumulated evidence indicates that elevated CRP in later life is 
predicted by a range of prenatal exposures [e.g., maternal depression and social adversity (Plant 
et al., 2016, Slopen et al., 2015)], and childhood adversities [e.g., trauma/maltreatment, bullying, 
and economic/social disadvantage (Baumeister et al., 2016, Copeland et al., 2014, Slopen et al., 
2015)]. Thus, the associations that we observed in this sample of children enriched for 
psychopathology might reflect a general effect of childhood adversity on both inflammation and 
cognitive functioning. Further research, utilising larger samples, is needed to explore the 
potentially mediating role of childhood adversity.  
4.2. Implications  
Our findings lend further credence to the notion that the relationships between CRP and 
cognitive impairments observed among individuals with psychiatric disorder, older adults, and 
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individuals with underlying physical health problems are not merely epiphenomena. Whilst the 
associations observed in these populations may be confounded by illness chronicity, medication 
effects, or neuroanatomical changes, such confounders are minimised in this sample of 
adolescents enriched for psychopathology. Moreover, our findings show that these associations 
are present in early life before the onset of severe psychiatric disorders. Collectively, our 
findings and those previous studies, tentatively suggest that novel treatments targeting 
systemic inflammation might lead to a reduction in persistent cognitive symptoms among 
psychiatric patients. Such treatment developments are welcomed given that the cognitive 
features that characterise psychiatric disorders often show only small-to-moderate responses to 
pharmacological treatments (Mishara and Goldberg, 2004, Rosenblat et al., 2015). One such 
candidate might be statin therapy, administration of which has been found to attenuate 
circulating CRP concentration (Albert et al., 2001) and has also been associated with a reduction 
in cognitive symptoms among individuals with Alzheimer’s disease (Sparks et al., 2006). It 
remains a question for future research whether statin therapy might induce significant 
improvement in cognitive symptoms among those already diagnosed with psychiatric disorder, 
possibly by reducing circulating CRP concentration.  
4.3. Limitations 
Several limitations must be noted. Firstly, the current study is limited by the relatively small 
sample size, which may have reduced our ability to detect significant associations. Secondly, in 
this small sample, ‘psychopathology’ was defined as a score in the borderline/clinical range of 
the YSR and at least one somewhat/certainly true psychotic-like experience. Thus, our ability to 
detect significant interaction effects between CRP and psychopathology may have been limited 
by the fact that we used a leniently-defined threshold for psychopathology. A third limitation 
relates to the fact that we examined only CRP levels in saliva. A previous study using blood-
derived markers observed that poor cognitive performance was associated with elevated 
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inflammatory cytokines, but not CRP, among patients with depression (Goldsmith et al., 2016). 
Our failure to find significant associations between elevated CRP and memory performance, or 
any moderating effect of psychopathology, might be because CRP (either in saliva or blood) is 
not a sufficiently sensitive measure of inflammation.  Finally, whilst saliva samples were typically 
obtained within one week of cognitive assessments, this was not always possible (mean lapse of 
time 1.4 months). As CRP levels may change over time, this delay may have reduced our ability 
to find significant associations between CRP and cognitive function.  
4.4. Conclusions 
Consistent with studies examining serum/plasma CRP among patients with psychiatric 
disorders, older adults, and individuals with physical health conditions, we have demonstrated 
that elevated salivary CRP is associated with poorer performance on measures of executive 
function in this sample of children aged 11-14 years that is enriched for those presenting with 
psychopathology. In contrast to expectations, psychopathology did not appear to modify the 
effect of CRP on cognition. Our findings obtained in this sample of relatively healthy adolescents, 
where confounding factors such as medication use, illness chronicity, and neuroanatomical 
changes are minimised, provide further evidence to suggest that the association between CRP 
and cognitive function is not merely an epiphenomenon, though the absence of blood-derived 
CRP data prevents us from drawing definitive conclusions regarding the role of peripheral 
inflammation in cognitive function. Nevertheless, the robust associations that we observed in 
this sample of adolescents between salivary CRP and executive function, which withstood 
adjustment for a range of factors, provide exciting prospects for intervention strategies aimed at 
reducing cognitive impairments in vulnerable populations.  
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Table 1. Memory and executive function measures completed by participants 
Cognitive measure and subtest Normative data Subtest description 
 Mean  (SD)  
Memory: WRAML2 subtests    
Number-letter 10 (3) Repeating strings of numbers and letters presented orally 
Verbal memory index  100 (15)  
Story memory   Immediate recall of two short stories presented orally 
Verbal learning    Immediate free recall of a list of words presented orally 
Visual memory index 100 (15)  
Design memory   Drawing five visually-presented geometric designs 
Picture memory   Identifying differences between four similar pairs of pictures 
Verbal working memory 10 (3) Immediate recall of word lists by category (animal vs. non-animal)  
Executive function: D-KEFS subtests    
Verbal fluency test    
Letter fluency 10 (3) Generating words beginning with F, A, and S within 60 s 
Category fluency 10 (3) Generating items from categories (animals and boys names) within 60 s 
Colour-word interference test    
Inhibition 10 (3) Naming the ink colour of colour-words presented in contrasting coloured ink  
Inhibition/switching 10 (3) 
Alternating between the Inhibition condition described above and naming the colour-word whilst 
ignoring ink colour 
Towers test    
Total achievement score 10 (3) Building towers using one to five disks in the fewest possible moves 
Note. WRAML2: Wide Range Assessment of Memory and Learning 2nd edition; D-KEFS: Delis–Kaplan Executive Function System. 
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Table 2. Sample demographics 
 
Total sample 
(N=107) 
Age (years); mean (SD) 13.2 (1.1) 
Male sex; n (%) 51 (48.1) 
BMI (kilograms/metres
2
); mean (SD) 19.8 (3.2) 
BMI categories    
Healthy weight 84 (80.8) 
Overweight 15 (14.4) 
Obese 5 (4.8) 
Ethnicity; n (%)   
White British 35 (32.7) 
White other 28 (26.2) 
Black African or Caribbean 12 (11.2) 
Other 32 (29.9) 
Socioeconomic status based on parental occupation; n (%)   
Higher managerial, administrative, and professional 67 (62.6) 
Intermediate  26 (24.3) 
Routine and manual  14 (13.1) 
Tobacco use; n (%)  2 (1.9) 
Cannabis use; n (%) 3 (2.8) 
Family history of psychosis; n (%) 
b
 29 (27.1) 
YSR Internalising ‘borderline/clinical’ range; n (%) 
c
 18 (17.1) 
YSR Externalising ‘borderline/clinical’ range; n (%) 
d
 11 (10.5) 
Reported ≥ 1 ‘somewhat true’ psychotic-like experience, n (%) 
e
 46 (43.0) 
WRAML2: Number letter; mean (SD) 12.2 (3.2) 
WRAML2: Verbal memory; mean (SD) 106.7 (12.7) 
WRAML2: Visual memory; mean (SD) 90.7 (13.2) 
WRAML2: Verbal working memory; mean (SD) 10.2 (2.3) 
D-KEFS: Letter fluency; mean (SD) 10.6 (2.7) 
D-KEFS: Category fluency; mean (SD) 12.5 (3.1) 
D-KEFS: CW Inhibition; mean (SD) 11.1 (2.3) 
D-KEFS: CW Inhibition/switching; mean (SD) 10.8 (2.3) 
D-KEFS: Towers test; mean (SD) 11.4 (1.9) 
Note. SD, standard deviation; BMI: Body Mass Index; YSR: Youth Self-Report; WRAML2: 
Wide Range Assessment of Memory and Learning 2nd edition; D-KEFS: Delis–Kaplan 
Executive Function System; CW: colour-word interference test.
 a
 Includes schizophrenia 
and schizoaffective disorder. 
b
 YSR Internalising: ‘borderline’ (n=6); ‘clinical’ (n=12); 
c
 YSR 
Externalising: ‘borderline’ (n=4); ‘clinical’ (n=7). 
e
 No. of somewhat or certainly-true PLEs 
reported: 1 (n=18); 2 (n=15); 3 (n=4); 4 (n=5); 5 (n=2); 6 (n=1); 8 (n=1). Missing data: BMI 
(n=3); WRAML2 number letter (n=3) WRAML2 verbal and visual memory indices (n=1); 
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WRAML2 verbal working memory (n=1); D-KEFS letter and category fluency (n=2); D-KEFS 
CW inhibition and inhibition/switching (n=3); D-KEFS tower test (n=2); YSR internalising 
(n=2); YSR externalising (n=2). 
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Table 3. Associations between C-reactive protein (CRP) and cognitive performance in 11-14 year-olds 
 
CRP adjusted for methodological/participant 
factors 
a
 
CRP adjusted for methodological/participant 
factors and psychopathology 
b
 
Interaction effects for 
psychopathology*CRP 
 β B (95% CI) p β B (95% CI) p β, p 
WRAML2: Number letter -0.14 -0.04 (-0.09 to 0.01) 0.14 -0.15 -0.04 (-0.09 to 0.01) 0.09 
INT*CRP (0.13, 0.73) 
EXT*CRP (0.03, 0.88) 
PLE*CRP (0.24, 0.54) 
WRAML2: Verbal memory 0.01 0.01 (-0.19 to 0.20) 0.94   0.03 0.03 (-0.16 to 0.22) 0.77 
INT*CRP (0.05, 0.88) 
EXT*CRP (0.09, 0.71) 
PLE*CRP (0.39, 0.26) 
WRAML2: Visual memory -0.05 -0.06 (-0.33 to 0.21) 0.68 -0.06 -0.07 (-0.33 to 0.19) 0.60 
INT*CRP (0.25, 0.45) 
 EXT*CRP (0.06, 0.88) 
PLE*CRP (0.30, 0.51) 
WRAML2: Verbal working memory -0.02 -0.00 (-0.05 to 0.05) 0.89 -0.01 -0.00 (-0.05 to 0.04) 0.90 
INT*CRP (-0.41, 0.42) 
 EXT*CRP (0.05, 0.92)  
PLE*CRP (-0.05, 0.93) 
D-KEFS: Letter fluency -0.24 -0.06 (-0.10 to -0.02) 0.006 -0.23 -0.06 (-0.10 to -0.01) 0.009 
INT*CRP (-0.41, 0.22) 
EXT*CRP (0.02, 0.92)  
PLE*CRP (0.12, 0.74) 
D-KEFS: Category fluency -0.17 -0.05 (-0.10 to 0.01) 0.08 -0.17 -0.05 (-0.10 to 0.01) 0.10 
INT*CRP (0.17, 0.78)  
EXT*CRP (-0.05, 0.92)  
PLE*CRP (0.38, 0.35) 
D-KEFS: CW Inhibition -0.28 -0.05 (-0.09 to -0.02) 0.004 -0.25 -0.05 (-0.09 to -0.01) 0.01 
INT*CRP (0.03, 0.96)  
EXT*CRP (0.40, 0.32)  
PLE*CRP (0.06, 0.87) 
D-KEFS: CW Inhibition/switching -0.36   -0.07 (-0.11 to -0.04) <0.001 -0.35 -0.07 (-0.11 to -0.03) <0.001 
INT*CRP (0.03, 0.92)  
EXT*CRP (0.55, 0.11)  
PLE*CRP (-0.16, 0.59) 
D-KEFS: Towers test -0.04 -0.01 (-0.05 to 0.04) 0.77 -0.04 -0.01 (-0.05 to 0.03) 0.74 
INT*CRP (1.02, 0.13)  
EXT*CRP (-0.11, 0.82) 
PLE*CRP (-0.21, 0.69) 
Note. WRAML2:  Wide Range Assessment of Memory and Learning 2nd edition; D-KEFS: Delis–Kaplan Executive Function System; CW: colour-word interference test; 
β standardised beta coefficient from linear regression analysis; B: unstandardised regression coefficients; CI: confidence interval. INT: internalising symptoms; EXT: 
externalising symptoms: PLE: psychotic-like experiences. All analyses performed with robust standard errors using square root transformed CRP. 
a
 Adjusted for day of 
saliva sample collection (Day 1 vs. Day 2) and recent dental problems; 
b
 additionally adjusted for current psychopathology (Youth Self-Report internalising scores in 
borderline or clinical range; Youth Self-Report externalising scores in borderline or clinical range; presence of at least one somewhat true psychotic-like experience).  
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Highlights  
  Salivary CRP predicts poorer executive functioning in children aged 11-14 years.  
  The association is not confounded or moderated by concurrent psychopathology.  
  Findings have implications for interventions targeting cognitive deficits.  
  Salivary CRP can be used to investigate inflammation-brain function relationships.  
 
 
